Immunic Appoints Experienced Biopharma Executive Jon Congleton to Board

Immunic Inc has appointed Jon Congleton to its board of directors, bringing nearly four decades of biopharmaceutical industry experience. Congleton has a background in drug development, commercialization, and executive leadership, with a focus on CNS conditions. He was involved in the US launch of Copaxone, a treatment for relapsing forms of multiple sclerosis, and currently serves as CEO of Mineralys Therapeutics. Congleton will support Immunic's advancement of its multiple sclerosis program through late-stage development.